miR-603 promotes cell proliferation and differentiation by targeting TrkB in acute promyelocytic leukemia

Arsenic trioxide (ATO) treatment effectively prolongs the overall survival of patients with acute promyelocytic leukemia (APL). Mutations in the oncogene PML::RARA were found in patients with ATO-resistant and relapsed APL. However, some relapsed patients do not have such mutations. Here, we performed microarray analysis of samples from newly diagnosed and relapsed APL, and found different microRNA (miRNA) expression patterns between these two groups. Among the differentially expressed miRNAs, miR-603 was expressed at the lowest level in relapsed patients. The expression of miR-603 and its predicted target tropomyosin-related kinase B (TrkB) were determined by PCR and Western blot. Proliferation was measured using an MTT assay, while apoptosis, cell cycle and CD11b expression were analyzed using flow cytometry. In APL patients, the expression of miR-603 was negatively correlated with that of TrkB. miR-603 directly targeted TrkB and downregulated TrkB expression in the APL cell line NB4. miR-603 increased cell proliferation by promoting the differentiation and inhibiting the apoptosis of NB4 cells. This study shows that the miR-603/ TrkB axis may be a potent therapeutic target for relapsed APL.

Automated summary

Treatment with arsenic trioxide (ATO) effectively prolongs the overall survival of patients with acute promyelocytic leukemia (APL). This study identified different microRNA expression patterns between newly diagnosed and relapsed APL patients, with miR-603 being expressed at the lowest level in relapsed patients. miR-603 directly targets tropomyosin-related kinase B (TrkB) and downregulates its expression in APL cells, promoting cell proliferation by inhibiting apoptosis and promoting differentiation.